Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

Rheumatology Research Foundation Investigators’ Meeting Shares Advancements Toward a Cure

From the College  |  September 7, 2016

The Rheumatology Research Foundation hosted the 9th annual Investigators’ Meeting in Atlanta on June 24–25. As a requirement for Foundation innovative research and pilot grant recipients, Foundation-funded investigators meet annually to provide updates and status reports on the work they are doing to advance treatments and cures for rheumatic diseases. More than 50 attendees enjoyed…

Filed under:From the CollegeResearch Rheum Tagged with:Advocacycureinvestigatorspatient carerheumatologyRheumatology Research Foundation

The Patient's Choice

When Rheumatologists Are a Patient’s Second or Third Choice for Medical Opinion

Charles Radis, DO  |  September 7, 2016

Outside Exam Room No. 5, the chart rack was empty, so I assumed my new consult was late. Just in case, I looked back over my shoulder as I passed by the partially open door and glimpsed the lower half of a woman holding a three-ringed binder on her lap. I squinted and took a…

Filed under:ConditionsPractice SupportPsoriatic Arthritis Tagged with:ArthritisLyme Diseasepatient carePractice ManagementPsoriatic ArthritisRheumatic Diseaserheumatologist

FDA Approves Etanercept-szzs Biosimilar

Michele B. Kaufman, PharmD, BCGP  |  September 2, 2016

Although it may not be available until 2017, the FDA approved the use of etanercept-szzs for multiple autoimmune diseases…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsetanerceptetanercept-szzsFDAFood and Drug Administration

Novartis Bid to Sell New Biosimilar Crimped by U.S. Court Battles

John Miller  |  September 1, 2016

ZURICH (Reuters)—Novartis has won U.S. approval for a copy of Amgen’s blockbuster arthritis drug Enbrel, but the Swiss drugmaker’s bid to muscle in on the medicine’s $4.7 billion in annual U.S. revenue remains blocked by court battles. Novartis’s Sandoz unit said on Tuesday the U.S. Food and Drug Administration (FDA) approved Erelzi, its biosimilar copy…

Filed under:Biologics/DMARDsDrug UpdatesProfessional Topics Tagged with:Biologics & BiosimilarsEnbrelNovartis

U.S. FDA Approves Biosimilar to Etanercept

Reuters Staff  |  August 30, 2016

(Reuters)—The U.S. Food and Drug Administration on Tuesday approved Novartis AG’s biosimilar version of Amgen Inc.’s arthritis drug etanercept (Enbrel). The FDA approved the drug, Erelzi, known also as etanercept-szzs, for multiple inflammatory conditions, including rheumatoid arthritis and plaque psoriasis, a skin condition. The agency approved the drug as a biosimilar, meaning there is no…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsetanerceptetanercept-szzsFDAFood and Drug Administration

Clazakizumab for Adults with Active PsA

Arthritis & Rheumatology  |  August 30, 2016

This is the first clinical trial of an IL-6–targeted therapy in PsA. Clazakizumab may be an effective treatment option for musculoskeletal aspects of PsA, but because of the lack of a dose response in this study, further studies are required to confirm the appropriate dose. The safety profile is consistent with the pharmacology of IL-6 blockade and prior clinical experience with this antibody in rheumatoid arthritis…

Filed under:ConditionsDrug UpdatesPsoriatic ArthritisResearch Rheum Tagged with:Arthritis & Rheumatologyclazakizumabclinical trialsInterleukinPsoriatic ArthritisResearch

FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab

Michele B. Kaufman, PharmD, BCGP  |  August 17, 2016

FDA advisory committees recommend the approvals of the abuse-deterrent opioid morphine sulfate for pain and brodalumab for plaque psoriasis…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:brodalumabFDAFood and Drug Administrationmorphine sulfateOpioidsPainplaque psoriasis

garagestock/shutterstock.com

E-Health, Telemedicine Pose Challenges, Offer Benefits for Patients with Arthritis

Michelle Burda, MLS, & Terence Starz, MD  |  August 11, 2016

A 52-year-old woman comes to the office complaining of a two-month history of pain and swelling in the small joints of her hands, feet and knees. She says, “Doctor, I’ve been searching the Internet, and I think I have rheumatoid arthritis. I have some questions for you.” The healthcare system in the U.S. is changing…

Filed under:ConditionsResearch RheumTechnology Tagged with:ArthritisInternetonlinepatient carepatient communicationResearchRheumatic DiseaserheumatologistrheumatologyTechnologytelehealthtelemedicine

Humira Found Partially Effective against Hidradenitis Suppurativa

Gene Emery  |  August 4, 2016

NEW YORK (Reuters Health) – The anti-inflammatory drug adalimumab can provide significant relief for about a quarter of people who suffer from a moderate-to-severe case of the chronic skin condition hidradenitis suppurativa, according to two 36-week trials. But the drug – which would cost over $104,000 per year for the weekly injections used in the…

Filed under:Biologics/DMARDsDrug Updates

Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting

Michele B. Kaufman, PharmD, BCGP  |  July 15, 2016

In July, the FDA’s Arthritis Advisory Committee will meet and review proposed biosimilars for etanercept and adalimumab to treat multiple rheumatic diseases…

Filed under:Biologics/DMARDsDrug Updates Tagged with:adalimumabBiosimilarsetanerceptFDAFood and Drug Administration

  • « Previous Page
  • 1
  • …
  • 37
  • 38
  • 39
  • 40
  • 41
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences